Benfer David
Known title: DirectorCIK: 0001325119
Associated companies
Transaction History
| STXS | ▲ Buy | Grant | 43,103 | $0 | 7/1/2026 | View on chart |
| STXS | ▲ Buy | Grant | 46,948 | $0 | 1/2/2026 | View on chart |
| STXS | ▲ Buy | Grant | 43,668 | $0 | 7/1/2025 | View on chart |
| STXS | ▲ Buy | Grant | 56,497 | $0 | 1/2/2025 | View on chart |
| STXS | ▲ Buy | Grant | 53,475 | $0 | 7/1/2024 | View on chart |
| STXS | ▲ Buy | Grant | 64,935 | $0 | 1/2/2024 | View on chart |
| STXS | ▲ Buy | Grant | 47,619 | $0 | 7/3/2023 | View on chart |
| STXS | ▲ Buy | Grant | 54,054 | $0 | 1/3/2023 | View on chart |
| STXS | ▲ Buy | Grant | 15,527 | $0 | 7/1/2022 | View on chart |
| STXS | ▲ Buy | Grant | 10,449 | $0 | 1/4/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
No recent news for STXS
There are no new developments for Stereotaxis Inc. in the past week. The company continues to trade near its 12‑month low, with an RSI of 22.8 indicating oversold conditions. The 52‑week range remains $1.09 to $3.59, and analysts maintain a target of $3.00.
No recent news for STXS. There are no new developments for Stereotaxis Inc. in the past week. The company continues to trade near its 12‑month low, with an RSI of 22.8 indicating oversold conditions. The 52‑week range remains $1.09 to $3.59, and analysts maintain a target of $3.00.